What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Neuralink disclosed in May 2024 that some threads in its first human participant’s brain implant had retracted, reducing the number of electrodes able to record neural signals. The company said a software change restored signal monitoring. It has not established that air in the skull caused the retraction; that explanation remains unconfirmed in the sources reviewed.
What happened to Neuralink’s first participant?
Neuralink’s first human implantation took place in January 2024 as part of its PRIME Study, an investigation of an implant, surgical robot and software intended to help people with paralysis control external devices. In a company update reported by Reuters in May 2024, Neuralink said “a number of threads retracted from the brain.” Reuters reported that the change left fewer electrodes able to measure brain signals.
Neuralink did not disclose how many of the implant’s 64 threads were displaced or no longer collecting data, according to Reuters. No population-level rate of thread retraction is established in the available reporting, so this episode should not be treated as evidence of how often the problem occurs.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →How did Neuralink respond?
The company said it modified the signal-processing algorithm to make it more sensitive and restored the implant’s ability to monitor the participant’s signals. That is Neuralink’s account of a software mitigation; it does not independently show that the mechanical issue was resolved.
#1 Best Overall
On July 10, 2024, Neuralink executive Dongjin “D.J.” Seo told Reuters that the threads were by then “more or less very stable.” Seo attributed this to tissue taking time after surgery to grow in and anchor the threads. This was a company executive’s assessment at that time, not an independent long-term performance finding.
Was air in the skull the cause?
The available sources do not confirm that air in the skull caused the threads to retract. Reuters reported that Neuralink discussed measures for later implants that included sculpting the skull surface to reduce the gap beneath the implant and lowering elevated carbon-dioxide concentration in patients’ blood to normal levels. Those planned mitigations do not establish what caused the first participant’s threads to move.
Neuralink’s progress page and the Reuters reports establish that retraction occurred and describe the company’s response, but do not directly link the original displacement to intracranial air. The cause remains unresolved in those sources; they do not prove either that air caused the retraction or that it played no role.
What is the PRIME Study implant?
Neuralink’s PRIME Study brochure describes the N1 Implant, R1 Robot and N1 User App as investigational. The implant records neural activity through 1,024 electrodes distributed across 64 threads, each thinner than a human hair. The study is intended to assess safety and initial effectiveness for helping participants with paralysis control external devices.
The brochure describes an approximately 18-month primary study phase followed by approximately five years of long-term follow-up—about six years overall. These are planned study durations, not proof that safety or effectiveness has already been established. The brochure explicitly says the study devices are not for sale.
What does FDA study authorization mean?
An FDA investigational-device exemption allows a qualifying clinical investigation to proceed; it is not marketing approval and does not establish that a device is proven safe or effective. The Associated Press reported the FDA’s explanation that an exemption generally allows a sponsor to begin a study in patients who meet its inclusion criteria. Clinical trials gather evidence on safety and effectiveness.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What changes did Neuralink describe for future implants?
Reuters reported that Neuralink head of neurosurgery Matthew MacDougall described a plan to sculpt the skull surface more intentionally in upcoming implants. He said this was intended to reduce the gap under the implant, bring it closer to the brain and reduce tension on the threads. This was a planned change for later procedures, not evidence that a confirmed cause had been identified or that the change had prevented recurrence.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
